NURSING EXAM TEST
[Author name]
[COMPANY NAME] [Company address]
,1
• Question 1
1 out of 1 points
Mr. McCullin is 64 years old with Parkinson’s disease. The
PMHNP caring for Mr. McCullin wants to start him on a
dopamine agonist to help manage and treat his condition.
The PHMNP selects this agent because of which action it has
on patients like Mr. McCullin?
Selected D.
Answer:
D2 receptors are the primary binding site for
dopamine agonists.
• Question 2
1 out of 1 points
Ms. Hill is currently being treated for schizophrenia but has stopped taking her
medications due to some side effects she claims she was experiencing. She
presents to the clinic today with worsening symptoms. She is experiencing
anhedonia, agitation, attentional impairment, and affective blunting. Which one of
the symptoms mentioned is considered a positive symptom of schizophrenia?
Selected B.
Answer:
Agitation
• Question 3
1 out of 1 points
,2
The PMHNP evaluates the patient for “fear conditioning”
when he asks:
Selected A.
Answer:
Have you ever experienced any type
of trauma?
• Question 4
1 out of 1 points
While genes have potential to modify behavior, behavior can
also modify genes. How do genes impact this process?
Selected B.
Answer:
Changes made to proteins lead to changes
in behavior.
• Question 5
1 out of 1 points
The PMHNP is caring for a patient with schizophrenia and is
considering a variety of treatment approaches. The PHMNP
selects a viable treatment that is consistent with the
“dopamine hypothesis of schizophrenia.” What action does
the PMHNP anticipate this treatment having on the patient?
Selected B.
Answer:
Hyperactivity in the mesolimbic dopamine
pathway mediates the positive symptoms of
schizophrenia.
• Question 6
1 out of 1 points
A patient is diagnosed with schizophrenia. What increases the
patient’s potential to mediate the cognitive symptoms of the
disease?
, 3
Selected A.
Answer:
Achieving underactivity of the mesocorticol
projections to the prefrontal cortex
• Question 7
1 out of 1 points
[Author name]
[COMPANY NAME] [Company address]
,1
• Question 1
1 out of 1 points
Mr. McCullin is 64 years old with Parkinson’s disease. The
PMHNP caring for Mr. McCullin wants to start him on a
dopamine agonist to help manage and treat his condition.
The PHMNP selects this agent because of which action it has
on patients like Mr. McCullin?
Selected D.
Answer:
D2 receptors are the primary binding site for
dopamine agonists.
• Question 2
1 out of 1 points
Ms. Hill is currently being treated for schizophrenia but has stopped taking her
medications due to some side effects she claims she was experiencing. She
presents to the clinic today with worsening symptoms. She is experiencing
anhedonia, agitation, attentional impairment, and affective blunting. Which one of
the symptoms mentioned is considered a positive symptom of schizophrenia?
Selected B.
Answer:
Agitation
• Question 3
1 out of 1 points
,2
The PMHNP evaluates the patient for “fear conditioning”
when he asks:
Selected A.
Answer:
Have you ever experienced any type
of trauma?
• Question 4
1 out of 1 points
While genes have potential to modify behavior, behavior can
also modify genes. How do genes impact this process?
Selected B.
Answer:
Changes made to proteins lead to changes
in behavior.
• Question 5
1 out of 1 points
The PMHNP is caring for a patient with schizophrenia and is
considering a variety of treatment approaches. The PHMNP
selects a viable treatment that is consistent with the
“dopamine hypothesis of schizophrenia.” What action does
the PMHNP anticipate this treatment having on the patient?
Selected B.
Answer:
Hyperactivity in the mesolimbic dopamine
pathway mediates the positive symptoms of
schizophrenia.
• Question 6
1 out of 1 points
A patient is diagnosed with schizophrenia. What increases the
patient’s potential to mediate the cognitive symptoms of the
disease?
, 3
Selected A.
Answer:
Achieving underactivity of the mesocorticol
projections to the prefrontal cortex
• Question 7
1 out of 1 points
